Exosomal TAR DNA-binding protein-43 and neurofilaments in plasma of amyotrophic lateral sclerosis patients: A longitudinal follow-up study

[1]  Sojib Bin Zaman,et al.  Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. , 2017, The Lancet. Neurology.

[2]  P. Calabresi,et al.  Neurofilament light chain as a biomarker in neurological disorders , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[3]  T. H. Nguyen,et al.  Global, regional, and national burden of motor neuron diseases 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[4]  J. Kassubek,et al.  Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[5]  V. Bonetto,et al.  Role of Extracellular Vesicles in Amyotrophic Lateral Sclerosis , 2018, Front. Neurosci..

[6]  O. Pansarasa,et al.  Pathological Proteins Are Transported by Extracellular Vesicles of Sporadic Amyotrophic Lateral Sclerosis Patients , 2018, Front. Neurosci..

[7]  Suzie Chen,et al.  Exosomes released by metabotropic glutamate receptor 1 (GRM1) expressing melanoma cells increase cell migration and invasiveness , 2017, Oncotarget.

[8]  P. van Damme,et al.  Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[9]  Y. Itoyama,et al.  Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial , 2017, The Lancet Neurology.

[10]  Baorong Zhang,et al.  Exosomes in Parkinson’s Disease , 2017, Neuroscience Bulletin.

[11]  Zhiqiang Gao,et al.  Progress in Exosome Isolation Techniques , 2017, Theranostics.

[12]  Robert G. Miller,et al.  Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease. , 2017, The Cochrane database of systematic reviews.

[13]  G. Sobue,et al.  Exosome secretion is a key pathway for clearance of pathological TDP-43. , 2016, Brain : a journal of neurology.

[14]  A. Chiò,et al.  Projected increase in amyotrophic lateral sclerosis from 2015 to 2040 , 2016, Nature Communications.

[15]  N. Pearce,et al.  Neurofilament light chain , 2015, Neurology.

[16]  C. Théry,et al.  Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. , 2014, Annual review of cell and developmental biology.

[17]  A. Ludolph,et al.  Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[18]  M. Swash,et al.  Delayed diagnosis in ALS: The problem continues , 2014, Journal of the Neurological Sciences.

[19]  Gavin Giovannoni,et al.  Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  A Al-Chalabi,et al.  Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial , 2013, The Lancet Neurology.

[21]  Gerry Shaw,et al.  Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[22]  K. Tsai,et al.  Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43 , 2012, Proceedings of the National Academy of Sciences.

[23]  Veeranna,et al.  Neurofilaments at a glance , 2012, Journal of Cell Science.

[24]  O. Hardiman,et al.  Amyotrophic lateral sclerosis , 2011, The Lancet.

[25]  H. Mitsumoto,et al.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial , 2007, The Lancet Neurology.

[26]  H. Akiyama,et al.  TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. , 2006, Biochemical and biophysical research communications.

[27]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[28]  P. Verkade,et al.  Alzheimer's disease beta-amyloid peptides are released in association with exosomes. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[29]  V. Meininger.  Clinical Trials in ALS: What Did We Learn from Recent Trials in Humans? , 2006, Neurodegenerative Diseases.

[30]  D. Schoenfeld,et al.  A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis , 2003, Neurology.

[31]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[32]  V. Meininger,et al.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.